Inhibitor Therapeutics, Inc. (INTI)
USD 0.06
(20.0%)
USD 0.06
(20.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.94 Million USD | -25.27% |
| 2022 | 11.97 Million USD | 20271.4% |
| 2021 | 58.78 Thousand USD | -55.39% |
| 2020 | 131.75 Thousand USD | -85.36% |
| 2019 | 899.96 Thousand USD | -27.01% |
| 2018 | 1.23 Million USD | 60.54% |
| 2017 | 768.05 Thousand USD | -89.53% |
| 2016 | 7.33 Million USD | 728.36% |
| 2015 | 885.85 Thousand USD | 91.34% |
| 2014 | 462.97 Thousand USD | 4431.45% |
| 2013 | 10.21 Thousand USD | -98.91% |
| 2012 | 936.43 Thousand USD | -31.96% |
| 2011 | 1.37 Million USD | -77.61% |
| 2010 | 6.14 Million USD | -15.68% |
| 2009 | 7.29 Million USD | -12.89% |
| 2008 | 8.36 Million USD | -58.24% |
| 2007 | 20.03 Million USD | 110.88% |
| 2006 | 9.5 Million USD | -14.73% |
| 2005 | 11.14 Million USD | 1.28% |
| 2004 | 11 Million USD | 45.14% |
| 2003 | 7.58 Million USD | -3.09% |
| 2002 | 7.82 Million USD | -6.3% |
| 2001 | 8.34 Million USD | -19.29% |
| 2000 | 10.34 Million USD | 25.37% |
| 1999 | 8.25 Million USD | -20.67% |
| 1998 | 10.4 Million USD | 31.65% |
| 1997 | 7.9 Million USD | 1216.67% |
| 1996 | 600 Thousand USD | 215.79% |
| 1995 | 190 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 7.17 Million USD | -7.97% |
| 2024 Q1 | 7.79 Million USD | -12.91% |
| 2023 Q2 | 10.15 Million USD | -6.25% |
| 2023 Q3 | 9.6 Million USD | -5.42% |
| 2023 Q4 | 8.94 Million USD | -6.85% |
| 2023 FY | 8.94 Million USD | -25.27% |
| 2023 Q1 | 10.83 Million USD | -9.52% |
| 2022 Q4 | 11.97 Million USD | 18872.9% |
| 2022 Q3 | 63.11 Thousand USD | 63.87% |
| 2022 Q2 | 38.51 Thousand USD | -37.01% |
| 2022 FY | 11.97 Million USD | 20271.4% |
| 2022 Q1 | 61.14 Thousand USD | 4.01% |
| 2021 FY | 58.78 Thousand USD | -55.39% |
| 2021 Q3 | 92.51 Thousand USD | -32.23% |
| 2021 Q4 | 58.78 Thousand USD | -36.46% |
| 2021 Q1 | 138.06 Thousand USD | 4.79% |
| 2021 Q2 | 136.52 Thousand USD | -1.12% |
| 2020 Q4 | 131.75 Thousand USD | 27.02% |
| 2020 Q3 | 103.73 Thousand USD | -52.07% |
| 2020 Q2 | 216.4 Thousand USD | -45.53% |
| 2020 Q1 | 397.3 Thousand USD | -55.85% |
| 2020 FY | 131.75 Thousand USD | -85.36% |
| 2019 Q2 | 2.13 Million USD | 70.18% |
| 2019 FY | 899.96 Thousand USD | -27.01% |
| 2019 Q4 | 899.96 Thousand USD | -39.35% |
| 2019 Q3 | 1.48 Million USD | -30.39% |
| 2019 Q1 | 1.25 Million USD | 1.59% |
| 2018 Q3 | 1.83 Million USD | 54.72% |
| 2018 Q1 | 1.97 Million USD | 157.74% |
| 2018 FY | 1.23 Million USD | 60.54% |
| 2018 Q4 | 1.23 Million USD | -32.72% |
| 2018 Q2 | 1.18 Million USD | -40.17% |
| 2017 Q3 | 1.3 Million USD | -36.5% |
| 2017 Q2 | 2.06 Million USD | -25.72% |
| 2017 Q1 | 2.77 Million USD | -62.18% |
| 2017 FY | 768.05 Thousand USD | -89.53% |
| 2017 Q4 | 768.05 Thousand USD | -41.32% |
| 2016 Q1 | 420.64 Thousand USD | -52.52% |
| 2016 Q2 | 4.91 Million USD | 1068.53% |
| 2016 Q3 | 3.86 Million USD | -21.41% |
| 2016 Q4 | 7.33 Million USD | 89.97% |
| 2016 FY | 7.33 Million USD | 728.36% |
| 2015 Q2 | 2.18 Million USD | 1615.19% |
| 2015 Q3 | 1.54 Million USD | -29.22% |
| 2015 FY | 885.85 Thousand USD | 91.34% |
| 2015 Q1 | 127.67 Thousand USD | -72.42% |
| 2015 Q4 | 885.85 Thousand USD | -42.84% |
| 2014 Q4 | 462.97 Thousand USD | 9.42% |
| 2014 FY | 462.97 Thousand USD | 4431.45% |
| 2014 Q3 | 423.1 Thousand USD | 40.79% |
| 2014 Q2 | 300.51 Thousand USD | 2774.11% |
| 2014 Q1 | 10.45 Thousand USD | 2.34% |
| 2013 Q1 | 884.12 Thousand USD | -5.59% |
| 2013 FY | 10.21 Thousand USD | -98.91% |
| 2013 Q4 | 10.21 Thousand USD | 9022.32% |
| 2013 Q3 | 112.00 USD | -92.4% |
| 2013 Q2 | 1474.00 USD | -99.83% |
| 2012 Q1 | 1.3 Million USD | -5.36% |
| 2012 Q2 | 1.2 Million USD | -7.75% |
| 2012 Q3 | 978.23 Thousand USD | -18.58% |
| 2012 Q4 | 936.43 Thousand USD | -4.27% |
| 2012 FY | 936.43 Thousand USD | -31.96% |
| 2011 Q4 | 1.37 Million USD | -63.22% |
| 2011 Q3 | 3.74 Million USD | -2.05% |
| 2011 FY | 1.37 Million USD | -77.61% |
| 2011 Q2 | 3.82 Million USD | -38.57% |
| 2011 Q1 | 6.21 Million USD | 1.16% |
| 2010 Q2 | 6.45 Million USD | -8.2% |
| 2010 Q4 | 6.14 Million USD | -6.5% |
| 2010 Q3 | 6.57 Million USD | 1.84% |
| 2010 Q1 | 7.03 Million USD | -3.53% |
| 2010 FY | 6.14 Million USD | -15.68% |
| 2009 Q2 | 8.15 Million USD | 4.48% |
| 2009 Q1 | 7.8 Million USD | -6.7% |
| 2009 FY | 7.29 Million USD | -12.89% |
| 2009 Q4 | 7.29 Million USD | -7.37% |
| 2009 Q3 | 7.87 Million USD | -3.52% |
| 2008 Q1 | 17.94 Million USD | -10.45% |
| 2008 Q3 | 12.19 Million USD | -29.02% |
| 2008 Q4 | 8.36 Million USD | -31.39% |
| 2008 FY | 8.36 Million USD | -58.24% |
| 2008 Q2 | 17.18 Million USD | -4.24% |
| 2007 Q3 | 18.62 Million USD | -12.19% |
| 2007 Q4 | 20.03 Million USD | 7.6% |
| 2007 Q2 | 21.2 Million USD | 45.63% |
| 2007 Q1 | 14.56 Million USD | 53.26% |
| 2007 FY | 20.03 Million USD | 110.88% |
| 2006 Q4 | 9.5 Million USD | -7.81% |
| 2006 FY | 9.5 Million USD | -14.73% |
| 2006 Q1 | 10.74 Million USD | -3.55% |
| 2006 Q2 | 11.07 Million USD | 3.01% |
| 2006 Q3 | 10.3 Million USD | -6.9% |
| 2005 Q4 | 11.14 Million USD | -1.88% |
| 2005 Q3 | 11.35 Million USD | 1.56% |
| 2005 Q1 | 11.17 Million USD | 1.53% |
| 2005 Q2 | 11.18 Million USD | 0.11% |
| 2005 FY | 11.14 Million USD | 1.28% |
| 2004 Q2 | 10.44 Million USD | 25.35% |
| 2004 Q1 | 8.33 Million USD | 9.9% |
| 2004 FY | 11 Million USD | 45.14% |
| 2004 Q4 | 11 Million USD | 5.78% |
| 2004 Q3 | 10.4 Million USD | -0.4% |
| 2003 Q4 | 7.58 Million USD | 0.29% |
| 2003 Q2 | 7.67 Million USD | 0.24% |
| 2003 FY | 7.58 Million USD | -3.09% |
| 2003 Q1 | 7.65 Million USD | -2.15% |
| 2003 Q3 | 7.55 Million USD | -1.48% |
| 2002 Q4 | 7.82 Million USD | -4.34% |
| 2002 Q1 | 8.14 Million USD | -2.45% |
| 2002 Q2 | 8.03 Million USD | -1.31% |
| 2002 Q3 | 8.17 Million USD | 1.75% |
| 2002 FY | 7.82 Million USD | -6.3% |
| 2001 Q3 | 8.94 Million USD | -6.87% |
| 2001 FY | 8.34 Million USD | -19.29% |
| 2001 Q1 | 9.84 Million USD | -4.86% |
| 2001 Q2 | 9.6 Million USD | -2.35% |
| 2001 Q4 | 8.34 Million USD | -6.71% |
| 2000 Q3 | 10.91 Million USD | 24.36% |
| 2000 Q4 | 10.34 Million USD | -5.2% |
| 2000 FY | 10.34 Million USD | 25.37% |
| 2000 Q1 | 9.05 Million USD | 9.71% |
| 2000 Q2 | 8.77 Million USD | -3.07% |
| 1999 Q1 | 9.6 Million USD | -7.69% |
| 1999 Q2 | 8.6 Million USD | -10.42% |
| 1999 FY | 8.25 Million USD | -20.67% |
| 1999 Q4 | 8.25 Million USD | -2.94% |
| 1999 Q3 | 8.5 Million USD | -1.16% |
| 1998 FY | 10.4 Million USD | 31.65% |
| 1998 Q1 | 11.6 Million USD | 46.84% |
| 1998 Q2 | 10.9 Million USD | -6.03% |
| 1998 Q3 | 10.5 Million USD | -3.67% |
| 1998 Q4 | 10.4 Million USD | -0.95% |
| 1997 Q2 | 8.99 Million USD | 0.0% |
| 1997 Q3 | 3.5 Million USD | -61.07% |
| 1997 Q4 | 7.9 Million USD | 125.71% |
| 1997 FY | 7.9 Million USD | 1216.67% |
| 1996 FY | 600 Thousand USD | 215.79% |
| 1995 FY | 190 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -387309.307% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -357.012% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 15.206% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1520.871% |
| Rebus Holdings, Inc. | 5000.00 USD | -178883.1% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.127% |
| Qrons Inc. | 420.00 USD | -2130651.19% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1061.257% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 67.975% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1762.246% |
| Skye Bioscience, Inc. | 11.94 Million USD | 25.052% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 76.963% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -23.954% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -11620.611% |
| SQZ Biotechnologies Company | 107.18 Million USD | 91.651% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -524.927% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -12266.69% |
| Mesoblast Limited | 667.9 Million USD | 98.66% |
| Marizyme, Inc. | 22.01 Million USD | 59.35% |
| Genus plc | 1.02 Billion USD | 99.13% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -558.824% |
| Pharming Group N.V. | 462.85 Million USD | 98.067% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -170.121% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1693.278% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1327.297% |
| ContraFect Corporation | 20.67 Million USD | 56.723% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2192.504% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2241.626% |
| IMV Inc. | 31.33 Million USD | 71.439% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -115.849% |
| MultiCell Technologies, Inc. | 126.22 USD | -7090024.386% |
| ONE Bio Corp. | 70.08 Million USD | 87.231% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -852.353% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.036% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1972.936% |
| Q BioMed Inc. | 3.51 Million USD | -154.562% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 74.561% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3325.16% |
| Biomind Labs Inc. | 73.81 Thousand USD | -12023.105% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.995% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -517.676% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 70.184% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -225.858% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1201.722% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -243.776% |
| GB Sciences, Inc. | 103.44 Thousand USD | -8551.375% |
| Alpha Cognition Inc. | 2.45 Million USD | -264.948% |
| HST Global, Inc. | 1526.00 USD | -586345.282% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -805.815% |
| Halberd Corporation | 10.13 Thousand USD | -88234.37% |
| Enzolytics Inc. | 361.7 Million USD | 97.526% |
| Agentix Corp. | 261.39 Thousand USD | -3323.653% |
| Resverlogix Corp. | 8.11 Million USD | -10.279% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -376.556% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.803% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 81.239% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1299.057% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -39183.416% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -21.309% |
| Zenith Capital Corp. | 7410.00 USD | -120671.323% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.736% |
| Ember Therapeutics, Inc. | 184.00 USD | -4863571.196% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2680.916% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3324.02% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -864.389% |
| Kadimastem Ltd | 2.3 Million USD | -288.405% |
| Helix BioMedix, Inc. | 3.02 Million USD | -195.831% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 83.019% |
| BioStem Technologies, Inc. | 14.56 Million USD | 38.537% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -15574.423% |
| LadRx Corporation | 2.3 Million USD | -287.765% |
| Cell Source, Inc. | 195.17 Thousand USD | -4485.289% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2430.748% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2430.748% |
| NovAccess Global Inc. | 62.24 Thousand USD | -14276.615% |
| Affymax, Inc. | 7.44 Million USD | -20.236% |
| Itoco Inc. | 1.4 Million USD | -539.192% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -9255.463% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -8342.599% |
| Mobile Lads Corp. | 52.00 USD | -17209813.462% |
| CytoDyn Inc. | 11.13 Million USD | 19.638% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -6159.376% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -49951.202% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2221.616% |
| SYBLEU INC | 330.46 Thousand USD | -2608.025% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2085.802% |
| International Stem Cell Corporation | 5.39 Million USD | -66.033% |
| Bioxytran, Inc. | 137.63 Thousand USD | -6401.951% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 40.346% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 46.021% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -11228.044% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -934.971% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -19.052% |
| Neutra Corp. | 2851.00 USD | -313795.3% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 72.384% |
| PureTech Health plc | 693.97 Million USD | 98.71% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -10.879% |
| IXICO plc | 15.84 Million USD | 43.517% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -8.055% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.339% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Cellectis S.A. | 333.99 Million USD | 97.321% |